Development of Nitric Oxide-Donating Netarsudil Derivatives as a Synergistic Therapy for Glaucoma with Reduced Ocular Irritation
Journal of Medicinal Chemistry · 26.09.2024 · 67 (18) · 16311-16327
DOI: 10.1021/acs.jmedchem.4c01199 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 20.08.2024. Verfasst von Cunrui Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211198, China. Hauptthemen laut MEDLINE: Glaucoma, rho-Associated Kinases, Nitric Oxide, Nitric Oxide Donors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Natural Science Foundation of Xinjiang Uygur Autonomous Region, China Pharmaceutical University, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Based on the synergistic therapeutic effect of nitric oxide (NO) and Rho-associated protein kinase (ROCK) inhibitors on glaucoma, a series of NO-donating Netarsudil derivatives were designed, synthesized, and their activities in vitro and in vivo were evaluated. Among them, (S)-10e released an appropriate amount of NO in aqueous humor in vitro and displayed potent ROCK inhibition. Topical administration of (S)-10e significantly lowered intraocular pressure in an acute ocular hypertension rabbit model and protected retinal ganglion cells in a magnetic microbead occlusion mouse model. A metabolism investigation revealed that (S)-10e released 7a, a metabolite after NO releasing, and 13, an active metabolite of (S)-Netarsudil, in rabbit eyes. Notably, introducing an NO donor moiety attenuated ROCK inhibition-induced ocular irritation in an sGC-independent manner, suggesting that the attenuated conjunctival hyperemia effect of (S)-10e is related to the NO-induced protein S-nitrosation of phosphodiesterase 3A (PDE3A). Overall, (S)-10e is a promising candidate for glaucoma treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211198, China.
- School of Pharmacy, Key Laboratory of Active Components of Xinjiang Natural Medicine and Drug Release Technology, Engineering Research Center of Xinjiang and Central Asian Medicine Resources, Xinjiang Medical University…
ORCID-Profile: Hui Ye, Yihua Zhang, Jianbing Wu, Zhangjian Huang
Förderung
- Natural Science Foundation of Xinjiang Uygur Autonomous Region
- China Pharmaceutical University
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia
Zitieren
APA
Li, C., Zhu, M., Liu, S., Zhang, J., Ye, H., Zhang, C., Ji, D., Tang, H., Zhang, Y., Wu, J., & Huang, Z. (2024). Development of Nitric Oxide-Donating Netarsudil Derivatives as a Synergistic Therapy for Glaucoma with Reduced Ocular Irritation. Journal of Medicinal Chemistry, 67(18), 16311-16327. https://doi.org/10.1021/acs.jmedchem.4c01199
Vancouver
Li C, Zhu M, Liu S, Zhang J, Ye H, Zhang C, et al. Development of Nitric Oxide-Donating Netarsudil Derivatives as a Synergistic Therapy for Glaucoma with Reduced Ocular Irritation. Journal of Medicinal Chemistry. 2024;67(18):16311-16327. doi:10.1021/acs.jmedchem.4c01199
BibTeX
@article{Li2024,
author = {Li, Cunrui and Zhu, Mingchao and Liu, Songqi and Zhang, Jiaming and Ye, Hui and Zhang, Chen and Ji, Duorui and Tang, Haoyang and Zhang, Yihua and Wu, Jianbing and Huang, Zhangjian},
title = {Development of Nitric Oxide-Donating Netarsudil Derivatives as a Synergistic Therapy for Glaucoma with Reduced Ocular Irritation},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {18},
pages = {16311--16327},
doi = {10.1021/acs.jmedchem.4c01199}
}
EUVIMED